| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/22/2022 | — | Maxim Group | Downgrades | Buy → Hold | |
| 05/17/2022 | 1354.9% | Truist Securities | $7 → $3 | Maintains | Buy |
| 05/17/2022 | 1354.9% | Needham | $8 → $3 | Maintains | Buy |
| 03/31/2022 | 3779.73% | Needham | $12 → $8 | Maintains | Buy |
| 10/13/2021 | 4749.66% | Truist Securities | → $10 | Initiates Coverage On | → Buy |
| 10/06/2021 | 5719.59% | Needham | → $12 | Initiates Coverage On | → Buy |
| 09/29/2021 | 6204.56% | Maxim Group | → $13 | Initiates Coverage On | → Buy |
| 09/20/2021 | 5719.59% | Oppenheimer | → $12 | Initiates Coverage On | → Outperform |
| 09/20/2021 | 9599.32% | Cantor Fitzgerald | → $20 | Initiates Coverage On | → Overweight |
Clarus Therapeutics Hldgs Questions & Answers
The latest price target for Clarus Therapeutics Hldgs (NASDAQ: CRXT) was reported by Maxim Group on August 22, 2022. The analyst firm set a price target for $0.00 expecting CRXT to fall to within 12 months (a possible -100.00% downside). 9 analyst firms have reported ratings in the last year.
The latest analyst rating for Clarus Therapeutics Hldgs (NASDAQ: CRXT) was provided by Maxim Group, and Clarus Therapeutics Hldgs downgraded their hold rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Clarus Therapeutics Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Clarus Therapeutics Hldgs was filed on August 22, 2022 so you should expect the next rating to be made available sometime around August 22, 2023.
While ratings are subjective and will change, the latest Clarus Therapeutics Hldgs (CRXT) rating was a downgraded with a price target of $0.00 to $0.00. The current price Clarus Therapeutics Hldgs (CRXT) is trading at is $0.21, which is out of the analyst's predicted range.